A novel vascular endothelial growth factor-trap KP-VR2 with enhanced ligand blocking | bioRxiv
Sequence of two vascular endothelial growth factor-Traps (VEGF-Traps).... | Download Scientific Diagram
Delivery of nVEGFi using AAV8 for the treatment of neovascular age-related macular degeneration - ScienceDirect
Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy | Scientific Reports
Aflibercept: a review of its use in the treatment of choroidal neovasc | OPTH
Role of the Fc Region in the Vitreous Half-Life of Anti-VEGF Drugs
Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration. - Abstract - Europe PMC
Effectiveness of Continued Ranibizumab Therapy in Neovascular Age-Related Macular Degeneration versus Switch to Aflibercept: Real World Evidence - Ophthalmology Retina
Cancers | Free Full-Text | Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data
Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations - Patricia A. Tang, Malcom J. Moore, 2013
Randomized clinical trial comparing intravitreal aflibercept combined with subthreshold laser to intravitreal aflibercept monotherapy for diabetic macular edema | Scientific Reports
IJMS | Free Full-Text | Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
Sequence of two vascular endothelial growth factor-Traps (VEGF-Traps).... | Download Scientific Diagram
Antiangiogenic therapy for ocular diseases: Current status and challenges - Chen - 2023 - MedComm – Future Medicine - Wiley Online Library
Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration | Journal of Translational Medicine | Full Text
aflibercept - List of Frontiers' open access articles
Treatment Of Ocular Diseases With Human Post-translationally Modified Vegf-trap Danos; Olivier ; et al. [REGENXBIO INC.]